Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 9/2007

01-09-2007 | Original Article

Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma

Authors: María José García-Velloso, Matías Jurado, Carolina Ceamanos, José Manuel Aramendía, María Puy Garrastachu, Guillermo López-García, José Ángel Richter

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 9/2007

Login to get access

Abstract

Purpose

This study was designed to retrospectively evaluate the diagnostic yield of FDG PET for the diagnosis of recurrent ovarian cancer.

Methods

Eighty FDG PET scans were performed on 55 patients owing to suspicion of relapse, and 45 FDG PET scans were performed on 31 patients who were clinically disease free. PET results were compared with the results of conventional radiological imaging (CIM) and serum CA 125 levels, and related to pathological findings in 54 cases or clinical follow-up in 71 cases.

Results

CIM correctly identified 49 cases with recurrence [sensitivity (SE) 53.3%] ,and there were 27 true negatives [specificity (SP) 81.8%] However, 43 cases were false negative and six were false positive. The positive predictive value (PPV), negative predictive value (NPV) and accuracy (ACC) of CIM were 89%, 38.6% and 60.8%, respectively. FDG PET correctly detected recurrent disease in 80/92 cases (SE 86.9%, p < 0.05) and ruled out relapse in 26/33 cases (SP = 78.8%). The PPV, NPV and ACC of PET were 91.9%, 68.4% and 84.8%, respectively. Standardised uptake values did not provide additional diagnostic accuracy compared with visual analysis. The CA 125 results showed an SE of 57.6%, an SP of 93.9% and an ACC of 67.2%. In 23 patients with positive serum CA 125 levels, but negative CIM, FDG PET was positive and relapse was confirmed. Furthermore, FDG PET was positive and relapse was confirmed in 11 patients with negative serum CA 125 levels and CIM.

Conclusion

FDG PET may detect recurrent ovarian cancer earlier than CIM, with higher sensitivity and even higher diagnostic accuracy.
Literature
1.
Boyle P, Leon ME, Maisonneuve P, Autier P. Cancer control in women. Update 2003. Int J Gynaecol Obstet 2003;83 Suppl 1:179–202.PubMedCrossRef
2.
Yancik R, Ries LG, Yates JW. Ovarian cancer in the elderly: an analysis of Surveillance, Epidemiology, and End Results Program data. Am J Obstet Gynecol 1986;154:639–47.PubMed
3.
International Federation of Gynecology and Obstetrics. Annual report on the results of treatment in gynecological cancer. Int J Gynecol Obstet. 1989;28:189–90.CrossRef
4.
Hoskins WJ, Pérez CA, Young RC, editors. Epithelial ovarian cancer. Principles and practice of gynecologic oncology. Philadelphia: Lippincott; 1992.
5.
Topuz E, Aydiner A, Saip P, Eralp Y, Tas F, Salihoglu Y, et al. Correlations of serum CA125 level and computerized tomography (CT) imaging with laparotomic findings following intraperitoneal chemotherapy in patients with ovarian cancer. Eur J Gynaecol Oncol 2000;21:599–602.PubMed
6.
Kubota K. From tumor biology to clinical PET: a review of positron emission tomography (PET) in oncology. Ann Nucl Med 2001;15:471–86.PubMed
7.
Karlan BY, Hawkins R, Hoh C, Lee M, Tse N, Cane P, et al. Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol 1993;51:175–81.PubMedCrossRef
8.
Casey MJ, Gupta NC, Muths CK. Experience with positron emission tomography (PET) scans in patients with ovarian cancer. Gynecol Oncol 1994;53:331–8.PubMedCrossRef
9.
Schröder W, Zimny M, Rudlowski C, Bull U, Rath W. The role of 18F-fluoro-deoxyglucose positron emission tomography (18F-FDG PET) in diagnosis of ovarian cancer. Int J Gynecol Cancer 1999;9:117–22.PubMedCrossRef
10.
Zimny M, Siggelkow W, Schroder W, Nowak B, Biemann S, Rath W, et al. 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol 2001;83:310–5.PubMedCrossRef
11.
Torizuka T, Nobezawa S, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, et al. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose. Eur J Nucl Med Mol Imaging 2002;29:797–803.PubMedCrossRef
12.
Kim S, Chung JK, Kang SB, Kim MH, Jeong JM, Lee DS, et al. [18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma. Eur J Nucl Med Mol Imaging 2004;31:196–201.PubMedCrossRef
13.
Hamacher K, Nebeling B, Blessing G. Computer aided synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose: a routine method of synthesis using tetrebutilammonium [18F]-fluoride. Appl Radiat Isot 1990;41:49–55.CrossRef
14.
Yancik R. Ovarian cancer: age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 1993;71:517–23.PubMedCrossRef
15.
Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991;9:1138–50.PubMed
16.
Chang WC, Hung YC, Kao CH, Yen RF, Shen YY, Lin CC. Usefulness of whole body positron emission tomography (PET) with 18F-fluoro-2-deoxyglucose (FDG) to detect recurrent ovarian cancer based on asymptomatically elevated serum levels of tumor marker. Neoplasma 2002;49:329–33.PubMed
17.
Rustin GJ, Nelstrop AE, Bentzen SM, Bond SJ, McClean P. Selection of active drugs for ovarian cancer based on CA125 and standard response rates in phase II trials. J Clin Oncol 2000;18:1733–9.PubMed
18.
Geary M, Foley M, Lenehan P. Recurrent ovarian carcinoma diagnosis and second-line therapy. Ir Med J 1995;88:698–700.
19.
Bristow RE, del Carmen MG, Pannu HK, Cohade C, Zahurak ML, Fishman EK, et al. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol 2003;90:519–28.PubMedCrossRef
20.
Tay EH, Grant PT, Gebski V, Hacker NF. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet Gynecol 2002;99:1008–13.PubMedCrossRef
21.
Zang RY, Li ZT, Tang J, Cheng X, Cai SM, Zhang ZY, et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer 2004;100:1152–61.PubMedCrossRef
22.
Onda T, Yoshikawa H, Yasugi T, Yamada M, Matsumoto K, Taketani Y. Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. Br J Cancer 2005;92:1026–32.PubMedCrossRef
23.
Garcia Velloso MJ, Boan Garcia JF, Villar Luque LM, Aramendia Beitia JM, Lopez Garcia G, Richter Echeverria JA. F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence. Comparison with CT scan and CA 125. Rev Esp Med Nucl 2003;22:217–23.PubMed
24.
Bristow RE, Giuntoli RL 2nd, Pannu HK, Schulick RD, Fishman EK, Wahl RL. Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. Gynecol Oncol 2005;99:294–300.PubMedCrossRef
25.
Ruiz-Hernandez G, Gomez MA, Delgado R, Sarandeses P, Llorente E, Jimenez A, et al. Recurrencia por cáncer de ovario: PET-18FDG versus tecnicas complementarias de imagen. Rev Esp Med Nucl 2003;22:148.
26.
Ruiz-Hernandez G, Delgado-Bolton RC, Fernandez-Perez C, Lapena-Gutierrez L, Carreras-Delgado JL. Meta-analysis of the diagnostic efficacy of FDG-PET in patients with suspected ovarian cancer recurrence. Rev Esp Med Nucl 2005;24:161–73.PubMedCrossRef
27.
Nakamoto Y, Saga T, Ishimori T, Mamede M, Togashi K, Higuchi T, et al. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. AJR Am J Roentgenol 2001;176:1449–54.PubMed
28.
Jimenez-Bonilla J, Maldonado A, Morales S, Salud A, Zomeno M, Roman J, et al. Clinical impact of 18F-FDG-PET in the suspicion of recurrent ovarian carcinoma based on elevated tumor marker serum levels. Clin Positron Imaging 2000;3:231–6.PubMedCrossRef
29.
Townsend DW, Beyer T. A combined PET/CT scanner: the path to true image fusion. Br J Radiol 2002;75:S24–30.PubMed
30.
Pannu HK, Cohade C, Bristow RE, Fishman EK, Wahl RL. PET-CT detection of abdominal recurrence of ovarian cancer: radiologic-surgical correlation. Abdom Imaging 2004;29:398–403.PubMedCrossRef
31.
Hauth EA, Antoch G, Stattaus J, Kuehl H, Veit P, Bockisch A, et al. Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer. Eur J Radiol 2005;56:263–8.PubMedCrossRef
32.
Kubik-Huch RA, Dorffler W, von Schulthess GK, Marincek B, Kochli OR, Seifert B, et al. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur J Radiol 2000;10:761–7.CrossRef
33.
Yen RF, Sun SS, Shen YY, Changlai SP, Kao A. Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Anticancer Res 2001;21:3691–4.PubMed
Metadata
Title
Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma
Authors
María José García-Velloso
Matías Jurado
Carolina Ceamanos
José Manuel Aramendía
María Puy Garrastachu
Guillermo López-García
José Ángel Richter
Publication date
01-09-2007
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 9/2007
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-007-0366-9

Other articles of this Issue 9/2007

European Journal of Nuclear Medicine and Molecular Imaging 9/2007 Go to the issue

Editorial commentary

Regional CBF changes in Parkinson’s disease: the importance of functional neuroimaging analyses

Original Article

Thyroid scintigraphy and perchlorate test after recombinant human TSH: a new tool for the differential diagnosis of congenital hypothyroidism during infancy

Original Article

Determination of tumour hypoxia with the PET tracer [18F]EF3: improvement of the tumour-to-background ratio in a mouse tumour model

Editorial

PET/CT in head and neck cancer

Short Communication

Simple and highly efficient synthesis of 3′-deoxy-3′-[18F]fluorothymidine using nucleophilic fluorination catalyzed by protic solvent

Original article

Quantitation, regional vulnerability, and kinetic modeling of brain glucose metabolism in mild Alzheimer’s disease